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Abstract: A remarkable percentage of acute gastroenteritis cases remain etiologically undiagnosed.
The aim of the study was to determine the prevalence of common and emerging enteric viruses, such
as novel human astroviruses, among undiagnosed samples from children with acute gastroenteritis.
Epidemiological studies for novel human astroviruses are still scarce. Stool samples collected over
two consecutive winter seasons (2016–2017) from children with gastroenteritis in Spain, which were
negative for bacteria, rotavirus, and adenovirus by routine diagnostics were screened by real-time
RT-PCR assays for the presence of classical and novel astrovirus, rotavirus, norovirus GI and GII,
sapovirus, and adenovirus. Overall, 220/384 stool samples (57.3%) were positive for at least one
virus. Co-infections were identified in 21% of cases. Among a total of 315 viruses identified,
adenovirus was the most prevalent (n = 103), followed by rotavirus (n = 51), sapovirus (n = 50),
classical astrovirus (n = 43), novel astroviruses (n = 42), and norovirus (n = 26). Novel astroviruses
were present in 13.3% of virus-positive cases. Most novel astroviruses were found in children
<2-year-old (30/39 children, 77%, p = 0.01) and were found in co-infection (66%). Only classical
astroviruses demonstrated significant differences in the Cq values during mono-infections compared
to co-infections. In conclusion, common enteric viruses may be frequently found in children with
undiagnosed gastroenteritis, indicating the need to implement more sensitive diagnostic methods.
Novel astroviruses circulate in the community and could be the cause of gastroenteritis among
young children.
Keywords: gastroenteritis; children; novel human astrovirus; classic astrovirus; norovirus; sapovirus;
rotavirus; adenovirus; epidemiology; real time RT-PCR
1. Introduction
Despite the large number of pathogens associated with acute gastroenteritis in children,
a remarkable percentage of cases remain etiologically undiagnosed, even in developed countries.
Among viral etiologies of sporadic acute gastroenteritis in children, rotavirus is historically the leading
pathogen, followed by norovirus and astrovirus, although implementation of the rotavirus vaccination
has decreased the incidence of rotavirus gastroenteritis in concerned countries [1]. The classical human
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astroviruses (HAstVs), first identified in 1975 during an outbreak of gastroenteritis in a maternity
ward [2], have been identified worldwide [3] since then. Several epidemiological studies have tried
to determine the exact prevalence of classical HAstVs [4], but there is a high heterogeneity among
studies depending on the studied population, the diagnostic method used, the timing of sampling,
and the geographic area; yet, there are currently few studies using real-time PCR assays. Overall, the
prevalence of classical HAstVs in children with acute gastroenteritis ranges between 0% and 30% [4].
Next-generation sequencing technologies have allowed us to identify two novel groups of highly
divergent HAstVs named MLB and VA/HMO. Sequences of novel HAstVs have been found in human
stools of individuals with diarrhea [5–8], but also in asymptomatic healthy controls [9,10]. Both groups
of novel HAstVs have been further divided into several genotypes: MLB1-3 for the MLB astroviruses
and VA1-5 for the VA astroviruses [3,4]. To date, no definitive association between novel astroviruses
and gastroenteritis has yet been established, but further epidemiologic studies have confirmed the
presence of novel HAstVs worldwide [9,11–16]. Interestingly, novel HAstVs have been associated with
unexpected central nervous system infections in—mostly immunocompromised—humans [17–23].
While novel astroviruses have been identified in every continent, data in Europe are scarce, and so far
only three countries have reported a systematic screening [12,14,18].
The aim of the study was to narrow down the diagnostic gap of acute gastroenteritis in children
by determining the prevalence of novel astroviruses in a pediatric population with undiagnosed
gastroenteritis, and to compare their prevalence with those of common enteric viruses, using sensitive
molecular diagnostic tools.
2. Materials and Methods
2.1. Patient and Sample Population
The study population was children ≤ 5-years-old presenting at outpatient clinics for symptoms
of gastroenteritis of unknown etiology. Stool samples had tested negative for enteropathogenic
bacteria (Salmonella spp., Shigella spp., Yersinia spp., Aeromonas spp., and Campylobacter spp.), rotavirus
or adenovirus by routine diagnostics, including immunochromatographic tests for viruses, at the
Laboratory of Microbiology of Hospital de Vall d’Hebron, which is one of the main hospitals covering
the Metropolitan Area of Barcelona (Spain). No clinical data were available except the patients’ age and
the date of stool collection. A total of 384 stool samples were randomly selected between January and
April 2016 and between January and April 2017. This period was chosen to focus on the winter season
and according to the higher incidence of viral gastroenteritis in the studied population. The study was
conducted in accordance with the Declaration of Helsinki, and was approved by the Clinical Research
Ethics Committee of the Hospital Universitari Vall d’Hebron (26 Feb 2016; PR(AG)32/2016).
2.2. Viral RNA Extraction and Real Time Polymerase- or Reverse-Transcription Polymerase Chain Reaction
(Real-Time PCR or Real-Time RT-PCR) Assays for Novel Astroviruses and other Enteric Viruses
RNA was extracted from 200 µL of a 30% stool suspension using the Viasure RNA-DNA Extraction
Kit (Certest Biotec, Zaragoza, Spain) following the manufacturer’s instruction. Real-time RT-PCR
specific assays for HAstV-MLB and HAstV-VA were performed using primers and probes previously
published [14]. The standard curves and positive controls for MLB1, MLB2, MLB2-3, VA1, VA2, VA3,
VA4 real-time RT-PCR assays were obtained using plasmid constructs kindly provided by Dr. S. Cordey
from the Geneva University Hospitals. Standard curves were constructed based on 10-fold serial
dilutions of the corresponding plasmid and analyzed in duplicate, for monoplex and duplex assays
(MLB1-MLB2/3, VA1-VA2, and VA3-VA4). Table 1 was adapted from Reference [14] and provides the
results of the monoplex and duplex validation assays. Real-time RT-PCR was performed using the
Kapa Probe Fast Universal One-Step real-time RT-PCR Master Mix (Kapa Biosystems, Wilmington, DE,
US) following the manufacturer’s instructions, on a Stratagene Mx3000P (Thermofischer, Waltham, MA,
US) and a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, US). Fifteen µL of
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the real-time RT-PCR master mix were mixed with 5 µL of extracted RNA. The reaction conditions
were as follows: 42 ◦C for 15 min, 95 ◦C for 5 min, then 40 cycles of 95 ◦C for 3 s, 55 ◦C for 20 s, 72 ◦C
for 10 s. Samples positive by MLB2-3 real-time RT-PCR assay were further screened with the specific
MLB2 real-time RT-PCR assay to confirm the genotype [14].
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Table 1. Nucleotide sequences of the primers and probes used and standard curves parameters of the novel HAstV real-time RT-PCR assays.
Standard Curve (10-Fold Serial Dilutions)
Monoplex Duplex
Assay VirusesDetected
Target Region
(ORF)/Amplicon
size (nt)
Fwd primer (5’-3’) 1 Probe (P) (5’-3’) 1 Rev Primer (5’-3’) 1
Final [uM]
Fwd/Rev/P Slope Intercept R
2 Slope Intercept R2
MLB1 MLB1 ORF2/68 GGTCTTGGAGCYCGAATTC
FAM—
TAGRGTTGGTTCAAATCT
—MGBNFQ
CGCTGTTTAATGCGCCAAA 0.6/0.6/0.25 −4.02 43.06 0.99 −3.5 40.10 0.97
MLB2–3 MLB2-MLB3 ORF1b/71 CCGAGCTCTTAGTGATGCTAGCT
FAM—
CGCTTCACTCGGAGAC
—MGBNFQ
CACCCCTCCAAATGTACTCCAA 0.6/0.6/0.2 −3.34 44.29 0.99 −3.19 44.69 0.99
VA1 VA1/HMO-C/SG/PS/UK1 ORF2/66 CCATCAGCAGTTACYGGGTCTGT
FAM—
TTTCCGCATATCCC
—MGBNFQ
CGTGGCTCCAGGTGAYTGT 0.6/0.6/0.2 −2.72 35.24 0.96 −2.83 36.03 0.97
VA2 VA2/HMO-A ORF2/67 CAGGGCCTGAATTACAAATTTCA
FAM—
CATTTATGCATCCTGCTTT
—MGBNFQ
GTGCCATCATTTGGCTCTTTC 0.9/0.9/0.25 −3.15 41.24 0.99 −2.71 37.96 0.98
VA3 VA3/HMO-B ORF1b/67 TTCCAGGCATTTGAGTTTGCT
FAM—
TTGAATCCGGATAAAAC
—MGBNFQ
CCCATCCTTCTCTCAGTTCATCA 0.6/0.6/0.25 −3.16 39.71 0.98 −3.25 40.39 0.97
VA4 VA4 ORF2/62 GATCCATGTATCGTGCATCGTT
FAM—
AACCTTACACAGTCCCCGG
—MGBNFQ
GCCCCCCCAAGATGTTG 0.9/0.9/0.25 −3.17 37.94 0.98 −2.5 35.83 0.95
1 Primers and probes were previously published [14].
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We also tested the presence of other enteric viruses in stool samples by real-time RT-PCR assays
targeting the classical HAstVs, sapovirus, rotavirus, adenovirus, and noroviruses GI and GII, which
were available for the 2017 study period only, using available commercial kits (VIASURE Astrovirus
Real Time PCR Detection Kit, VIASURE Sapovirus Real Time PCR Detection Kit, VIASURE Adenovirus
Real Time PCR Detection Kit, VIASURE Norovirus GI Real Time PCR Detection Kit, VIASURE
Norovirus GII Real Time PCR Detection Kit, and VIASURE Rotavirus Real Time PCR Detection Kit
from Certest Biotec; and RIDA®GENE Viral Stool Panel II from R-Biopharm).
2.3. Statistical Analyses
The Kruskal-Wallis test was used to compare continuous variables and Fischer exact test was
used to compare categorical variables. The non-parametric equality-of-medians test (Pearson chi2
test with continuity correction) was used to compare the proportion of Cq value above and under the
median, respectively, according to mono- or poly-infection status. p < 0.05 was considered statistically
significant. Statistics were performed by Stata /IC 13.1 (StataCorp, College Station, TX, USA).
3. Results
3.1. More than Half of Samples Undiagnosed by Routine Screening are Positive by Real-Time PCR- or
RT-PCR Assays
During the whole study period, 384 undiagnosed stool samples (n = 197 in 2016 and n = 187
in 2017) were analyzed. This selection of samples represents 24.2% of the total amount of samples
from outpatient children ≤5-years-old with gastroenteritis symptoms, and to 33.1% of undiagnosed
specimens. The overall proportion of undiagnosed samples during 2016 and 2017 was 77.7% (73.0%
during the studied period). The mean patients’ age was 1.6 years old. Of all analyzed samples, 101/197
(51%) and 119/187 (64%) samples were identified positive for at least one virus screened by the real-time
PCR or real-time RT-PCR assays. The proportion of samples that contained more than one viral target
was 13% and 28%, for 2016 and 2017, respectively (average of 21% for the total number of tested
samples). This led to a total of 133 and 182 distinct viruses identified in 2016 and 2017, respectively. In
2016, adenovirus was the most prevalent (47/197, 23.9%), followed by rotavirus and sapovirus (23/197
each, 11.7%), novel HAstVs (22/197, 11.2%), and classical HAstVs (15/197, 7.6%). In 2017, adenovirus
remained the most prevalent (56/187, 29.9%), followed by rotavirus and classical HAstVs (28/187
each, 15%), sapovirus (27/187, 14.4%), norovirus GII (22/187, 11.8%), and novel HAstVs (17/187, 9.1%).
Norovirus GI was found in only 4/187 samples (2.1%).
3.2. Diverse Novel HAstVs are Circulating in the Pa]ediatric Population, often in Children under 2 Years Old
and in Co-Infection with other Enteric Viruses
Prevalences of novel HAstVs were 11.2% (5.6% of HAstV-MLB and 5.6% of HAstV-VA) and 9.1%
(3.2% of HAstV-MLB and 5.9% of HAstV-VA) in 2016 and 2017, respectively. Among HAstV-MLB
and HAstV-VA, we found 10/3 MLB1 and 1/3 MLB2, 5/6 VA1, 3/2 VA2, 5/3 VA3, and 1/0 VA4 in
2016/2017, respectively. Of note, two samples were positive for several HAstVs-VA in 2016 (one double
co-infection VA1-VA2 and one triple co-infection VA1-VA2-VA3), leading to a total number of 25 novel
HAstVs identified in 2016; nevertheless, these samples were considered as mono-infected in the rest of
the study.
According to patients’ age, 84% (184/220) positive samples for any virus were identified among
children 0–3 years old (Figure 1A). Novel HAstV prevalence was highest in children under 2 years old
(30/39 positive samples, 77%; p = 0.01) (Figure 1B). For all viral targets except for NoV GI, for which
the number of positive samples was low, the age group with a higher positivity rate was the group
of one-year old children. For rotavirus, classic HAstV, and novel HAstV, this group was followed by
children younger than one year of age. For adenovirus, sapovirus, and norovirus GII, the second age
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group most affected was children 2 years-old. These same viral targets were also the ones occasionally
isolated in children 5 years of age.Viruses 2019, 11, x FOR PEER REVIEW 6 of 11 
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Figure 1. (A) Distribution of positive samples for any viral target by age groups. Percentages above
each bar indicate the positivity rate in each group category. (B) Percentage distribution of positive
samples by age group for each viral target. The number in brackets indicates the total number of positive
samples for each virus. AdV: adenovirus; RV: rotavirus; SaV: sapovirus; HAstV-C: classic human
astrovirus; HAstV-N: novel human astrovirus; NoV: norovirus: GI: genogroup I; GII: genogroup II.
As for most viruses, novel HAstVs were frequently found in co-infection: 76.4% of HAstV-MLB
and 54.5% of HAstV-VA positive samples (i.e., 66% of novel HAstV) were also positive for other enteric
viruses. Globally, we identified a higher rate of co-infection during 2017 than during the 2016 study
period (62.6% vs 42.3%, respectively). In comparison, co-infection was found in 48.5% of adenovirus,
49% of rotavirus, 56% of sapovirus, 58% of classical HAstVs, 63.6% of norovirus GII, and 50% of
norovirus GI cases. Figure 2 shows the number of samples and proportion of mono- and co-infections
identified per virus for each year analyzed. Overall, HAstV-MLB was identified in co-infection with
adenovirus (n = 8), rotavirus (n = 5), sapovirus (n = 4), and classical HAstV (n = 1). HAstV-VA was
identified in co-infection with classical HAstVs (n = 6), adenovirus (n = 5), norovirus GII (n = 2), and
rotavirus (n = 1). HAstV-MLB and HAstV-VA were found in triple co-infection in three and two
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samples, respectively, and HAstV-MLB was also found in one quadruple co-infection (Table S1). There
was no case of co-infections between HAstV-MLB and HAstV-VA genotypes.Viruses 2019, 11, x FOR PEER REVIEW 7 of 11 
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HAstV-VA: VA human astrovirus HAstV-C: classic human astrovirus; NoV: norovirus: GI: genogroup I;
GII: genogroup II; SaV: sapovirus; RV: rotavir s; AdV: adenovirus.
Mean global Cq values for novel HAstVs were 30.7 ± 6.7 for HAstV-MLB and 31.7 ± 6.4 for
HAstV-VA. Figure 3 shows the median Cq values and confidence intervals for novel astroviruses
(Figure 3A) and other enteric viruses (Figure 3B) during mono- and co-infections, respectively. There
was no significant statistical difference in the Cq value during co-infection compared to mono-infection
for any virus, except for classical HAstVs (p = 0.042 by Pearson Chi2 test with continuity correction).
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Figure 3. Median Cq values and confidence intervals for novel astroviruses (A) and other enteric
viruses (B) according to m n - or co-infection status. Rotavirus and adenovirus were excluded
from the analy is, as samples positive for these viruses by immunochromatography were excluded
from the study. There w s a st tistical diff rence when comparing the Cq value during co-infection
and mono-infection for classical HAstVs (p = 0.042 by Pearson chi2 test with continuity correction).
HAstV-MLB: MLB human astrovirus; HAstV-VA: VA human astrovirus HAstV-C: classic human
astrovirus; NoV: norovirus: GI: genogroup I; GII: genogroup II; SaV: sapovirus.
4. Discussion
In the present study we demonstrated that viral sequences belonging to one or several viruses
could be d t cted in 50%–65% of cas s of gastroenteritis of unknow etiology from an outpatient
pediatric population, when screened by sensi iv molecular assays. Th se results suggest that the wide
use of molecular assays on a routine basis might reduce the proportion of undiagnosed specimens
from children with gastroenteritis, which is currently ~75%, down to ~30%.
Viruses 2019, 11, 585 8 of 11
While most epidemiological studies on enteric viruses in children identified rotavirus as the
first viral cause of acute sporadic gastroenteritis [24–28], we found a higher positivity rate for
adenovirus, which could be biased on the fact that positive samples for rotavirus and adenovirus by
immunochromatography were excluded from the analyses. Yet, two other recent studies also identified
higher prevalence of adenovirus than rotavirus infection among a cohort of children with gastroenteritis
using real-time PCR assays [29,30], including one study that focused on the post rotavirus vaccine
era [30]. In addition, the possibility that the real-time PCR kit used for adenoviruses detects as well
other serotypes different from 40 and 41 with a lower efficiency cannot be completely ruled out. As
for rotavirus, despite that the prevalence reported in this study (11.7% in 2016 and 15% in 2017) does
not include samples that were positive by immunochromatographic tests, it is still remarkable, and
could be partially explained by the fact that the rotavirus vaccination coverage in Spain varies between
17%–50%, depending on the year and the area studied [31].
We included the screening for norovirus only during the 2017 study period. We found that
norovirus accounted for 14% of the virus-positive cases; similar to what was recently described by
Martinez Ascona et al. [26]. Norovirus screening contributed to an increase of 5% (10/187) of samples
with a microbiological diagnosis. The proportion of samples that remained undiagnosed decreased
from 48.7% in 2016 down to 36.4% in 2017. Genogroup II was predominant, accounting for 85% of
identified norovirus, as frequently described in sporadic cases of gastroenteritis [24,25,32].
While most epidemiological studies on classical HAstVs found a 2%–10% positivity rate during
acute gastroenteritis [4,13,33], we found an overall prevalence of 11.5%. An 18% positivity rate was
also identified by real-time RT-PCR methods in an Italian study [34], and up to 35% in a large cohort of
children among three continents [35]. In accordance with the fluctuation for classic HAstV infections
according to the year of sampling reported by several studies [3], the observed prevalence for classic
HAstV in our study varied between 7.6% in 2016 and 15% in 2017.
Finally, in addition to the most common well-characterized enteric viruses implicated in viral
gastroenteritis, we identified for the first time in Spain, a significant positivity rate for novel astroviruses,
with a prevalence of 11.2% in 2016 and 9.1% in 2017. Our overall 10% prevalence is by far one of the
highest described to date. While other studies found a positivity rate between 0%–6% [4,11–14], a
rate similar to ours was found only in Japan [15]. Like in other recent studies [11,12,15], we found
HAstV-MLB1 to be the most prevalent one. We detected no HAstV-MLB3 genotypes; interestingly, this
genotype was strongly associated with asymptomatic infections in a previous study [9]. Our overall
high positivity can be explained by the highly sensitive real-time RT-PCR assay we employed [36],
and also by the strict sample selection criteria: absence of a bacterial cause, symptomatic children ≤5
years old, outpatients and winter season. While the winter season is usually associated with peaks
of acute viral gastroenteritis [25,26,37], we cannot exclude that novel HAstV may have a different
(or no) seasonal pattern. Yet, in Germany, two peaks of HAstV detection were observed, between
February and May and between September and December [12], while in Thailand, the pattern of
seasonal distribution varied from one year to another [11].
For all viral targets included in the study, the proportion of samples presenting co-infections was
high, ranging between 27.5% and 83.5%. A similar high rate of co-infections during viral gastroenteritis
was also found in other studies using real-time RT-PCR techniques [34], including classical HAstVs
(77%–80%) [34,35]. Khamrin et al. also found overall 46% of co-infections among novel HAstV
positive cases [15]. This highlights that viral detection should be interpreted with caution in the
era of highly-sensitive molecular diagnostic tests (which detect viral sequences and not antigens).
When assessing whether viral load, estimated by the Cq value, could correlate with occurrence of
mono- or co-infections, we only found a statistical difference in the mean Cq value for the classical
HAstVs. This difference was not statistically significant for the MLB or VA HAstVs, but it is possible
that the sample size of the novel HAstVs was too small. Yet, even in the presence of a true viral
co-infection, the question is not as simple as to determine which pathogen is responsible for the disease,
but what is the respective contribution of each pathogen identified; specific interactions during viral
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co-infections should be further investigated by basic virological studies. Of note, for instance, using an
immunodeficient mouse model, astroviruses have been recently shown to be elements of the virome,
which can protect mice against murine norovirus and rotavirus infections [38].
In conclusion, our study provides additional information on novel HAstVs epidemiology in
Europe. As in Germany, UK, and Switzerland, novel HAstVs are circulating in Spain among children
with symptoms of gastroenteritis. In light of the high rate of co-infections, it remains to be determined
whether novel HAstVs are actual etiologic agents of acute gastroenteritis or only bystanders and/or
helpers versus controllers of other pathogens. Yet, our findings demonstrating the presence of one
or more viral agents in more than half of undiagnosed gastroenteritis by routine diagnostics in
children not only have clinical implications, such as the possible unnecessary use of antibiotics, but
also give clues for future research studies on viral interactions and their respective contribution to
gastroenteritis symptoms.
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